Dayvigo (Lemborexant) Non-Responder Profile: Who Doesn't Respond and Why

What the Clinical Trials Tell Us About Response Rates

Lemborexant produced statistically significant improvements in sleep onset and maintenance in both Phase 3 trials, but a notable proportion of participants still did not meet responder criteria [1][2].

In SUNRISE-1 (N=291, 30-day treatment period), lemborexant 10 mg reduced subjective sleep onset latency by 23.7 minutes versus 5.8 minutes for placebo [1]. That gap is real, but it also means some patients on active drug landed close to placebo performance. The trial defined a "responder" as achieving at least a 6-point reduction on the Insomnia Severity Index (ISI). Roughly 24% of patients on the 10 mg dose still did not meet that threshold by day 30 [1].

SUNRISE-2 (N=949, 12-month treatment) found that lemborexant 5 mg and 10 mg both outperformed placebo on subjective sleep efficiency and wake after sleep onset, with P<0.001 for both doses versus placebo at month 1 [2]. Even so, the 12-month data show a plateau in response: patients who did not improve by week 4 rarely improved further with continued treatment at the same dose [2].

Responder vs. Non-Responder in Trial Data

The FDA label summarizes effect sizes from both SUNRISE trials and notes that the 5 mg dose showed smaller effect sizes than the 10 mg dose on virtually every objective and subjective endpoint [3]. Patients randomized to 5 mg who did not respond were not systematically up-titrated mid-trial, which likely inflated the apparent non-responder rate at that dose.

A secondary analysis of SUNRISE-2 found that baseline ISI score above 21 (severe insomnia) predicted a smaller absolute ISI reduction with lemborexant compared to patients with moderate insomnia (ISI 15 to 20) [2]. Severe insomnia patients still improved, but fewer crossed the responder threshold, suggesting a ceiling effect at the approved maximum dose.

Objective vs. Subjective Discordance

Polysomnography data from SUNRISE-1 showed that lemborexant 10 mg reduced latency to persistent sleep by 17.9 minutes versus placebo (P<0.001) [1]. Some patients whose objective sleep improved still rated themselves as non-responders on subjective scales. This discordance is well-documented with orexin antagonists and may reflect hyperarousal that persists even when sleep architecture normalizes [4].

The Clinical Profile of a Dayvigo Non-Responder

Identifying who will not respond before prescribing saves weeks of ineffective treatment. Several patient characteristics correlate with poor outcomes in trial data and in real-world reports.

Untreated Psychiatric Comorbidity

Patients with active, untreated anxiety disorders, bipolar disorder, or PTSD consistently underperform on subjective sleep outcomes with orexin antagonists [4][5]. The orexin system modulates arousal, but hyperarousal driven by a dysregulated amygdala or sustained noradrenergic tone is not fully corrected by blocking OX1R and OX2R receptors alone [4].

The 2023 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline for Chronic Insomnia states: "Comorbid psychiatric conditions should be assessed and treated before or concurrently with pharmacotherapy for insomnia, as untreated comorbidities significantly attenuate hypnotic drug response" [5]. Patients who arrive at a Dayvigo prescription with a PHQ-9 above 15 or a GAD-7 above 14 and no concurrent behavioral or psychiatric treatment represent a high-risk group for non-response.

Concurrent Wake-Promoting Medications

Lemborexant's mechanism depends on reducing orexinergic drive to the wake-promoting circuits of the locus coeruleus and dorsal raphe [3]. Patients taking high-dose stimulants (amphetamine salts, modafinil, armodafinil) or certain antidepressants with potent norepinephrine reuptake inhibition may partially override the orexin blockade [6].

A pharmacodynamic interaction study found that co-administration of lemborexant with strong CYP3A4 inhibitors such as ketoconazole markedly increases lemborexant exposure, but co-administration with CYP3A4 inducers (rifampin, carbamazepine) reduces exposure by more than 80%, effectively rendering the drug sub-therapeutic [3]. Patients on enzyme-inducing anticonvulsants are functionally receiving a fraction of the intended dose.

Chronic Pain as the Primary Driver of Insomnia

Orexin antagonists do not treat pain. Patients whose insomnia is primarily driven by nociceptive or neuropathic pain frequently report that they feel "sleepy but unable to sleep" on lemborexant, a pattern consistent with the drug reducing wake drive without addressing the arousal stimulus [7].

In a cohort study of adults with comorbid insomnia and fibromyalgia, dual orexin receptor antagonists (including suvorexant) produced subjective improvement in only 31% of patients, versus 58% in a matched group without pain comorbidity [7]. Pain severity at baseline, measured by the Brief Pain Inventory, was the single strongest predictor of non-response [7].

Circadian Rhythm Disorders Misdiagnosed as Insomnia

Delayed sleep-wake phase disorder (DSWPD) and shift-work sleep disorder are sometimes misclassified as insomnia, and patients receive hypnotics rather than circadian-targeted therapy [8]. Lemborexant reduces arousal but does not shift the circadian clock. A patient with DSWPD who takes lemborexant at 11 PM but whose endogenous sleep window begins at 2 AM will likely report the drug "does nothing."

The AASM 2015 Clinical Practice Guideline for circadian rhythm sleep-wake disorders recommends actigraphy combined with a sleep diary over at least 7 days to confirm the diagnosis before pharmacotherapy [8]. Prescribers who skip this step may be placing circadian patients into insomnia treatment protocols.

Real-World Reports: What Patients Say on Reddit and Review Platforms

Aggregate patient reports from Reddit (r/insomnia, r/sleep), Drugs.com, and Trustpilot largely align with the trial-based non-responder profile, though anecdotal sources carry obvious limitations.

Common Non-Responder Complaints in Community Reports

The most frequent non-responder complaint across platforms is: "I feel groggy or drowsy but cannot actually fall asleep or stay asleep." This maps directly onto the objective-subjective discordance seen in trial data [1][4]. Patients describe a sensation of sedation without restorative sleep, which is distinct from the experience reported by responders, who typically describe a normal sleep onset with reduced middle-of-the-night waking.

A second recurring theme is disappointment after switching from z-drugs (zolpidem, eszopiclone). Patients accustomed to the rapid, forceful sedation of GABA-A modulators find lemborexant's softer onset unsatisfying, even when their actigraphy would show objective improvement. This is a perception issue, not a pharmacological failure, but it leads to discontinuation.

Patients with anxiety as the primary complaint report the lowest satisfaction. One recurring thread on r/insomnia describes lemborexant as "calming but not sedating enough when my mind is racing," which is consistent with the AASM guideline observation about psychiatric comorbidity [5].

Dose and Duration Patterns in Community Reports

Community reports suggest that a sizable share of eventual responders needed 4 to 6 weeks at 10 mg before noticing consistent benefit. Patients who abandoned Dayvigo after 1 to 2 weeks at 5 mg are likely underrepresented in the responder pool. This mirrors the SUNRISE-2 finding that ISI scores continued to decline between weeks 2 and 4 at 10 mg before plateauing [2].

Conversely, patients who saw no change by week 4 at 10 mg almost universally report no benefit at any subsequent point. This 4-week threshold is consistent with the prescribing information's recommendation to reassess treatment response at 4 weeks [3].

Pharmacological Reasons for Non-Response

Understanding the mechanism clarifies why certain patients fail.

OX2R Receptor Sensitivity Variation

Lemborexant is a dual antagonist at both OX1R and OX2R, with slightly higher affinity for OX2R [3]. Preclinical data suggest that OX2R plays the dominant role in maintaining wakefulness, but individual variation in receptor expression density may alter drug effect [6]. Patients with lower baseline orexin tone (such as older adults or those with narcolepsy type 2) may already have reduced orexinergic drive, leaving less room for pharmacological blockade to produce measurable improvement [6].

CYP3A4 Metabolism and Sub-Therapeutic Exposure

Lemborexant is primarily metabolized by CYP3A4 [3]. Without checking for drug-drug interactions, a prescriber may unknowingly be giving a patient a sub-therapeutic dose. Inducers of CYP3A4 include carbamazepine, phenytoin, rifampin, St. John's Wort, and chronic high-dose alcohol [3]. Any patient on these agents who reports non-response should have the drug interaction confirmed before assuming pharmacological failure.

The FDA label explicitly states: "Avoid use of lemborexant with moderate or strong CYP3A4 inducers" [3]. This is a contraindication that, if missed, produces a predictable non-response.

Half-Life Mismatch in Sleep Maintenance Insomnia

Lemborexant's mean half-life is approximately 17 to 19 hours [3]. For sleep-onset insomnia, this is longer than necessary. For sleep maintenance insomnia across an 8-hour window, it is generally adequate. However, patients with very early morning awakening (terminal insomnia) occurring 3 to 4 hours after sleep onset may have a primary pathophysiology that is not orexin-dependent, such as cortisol hypersecretion or REM dysregulation, and may not respond regardless of dose [4].

Distinguishing True Non-Response from Modifiable Factors

Before labeling a patient a non-responder, a structured review is warranted. The following four-step framework can be applied in a telehealth or office visit.

Step 1. Confirm the dose and duration. The patient must have completed at least 4 consecutive weeks at lemborexant 10 mg without missing more than 2 doses per week. Shorter trials or consistent use of the 5 mg dose in a patient without a specific contraindication to 10 mg do not constitute an adequate trial [3].

Step 2. Audit concurrent medications for CYP3A4 inducers. A single prescription for St. John's Wort or an enzyme-inducing anticonvulsant can render lemborexant essentially inactive [3][6].

Step 3. Screen for untreated psychiatric comorbidity. Administer the ISI, GAD-7, and PHQ-9. A GAD-7 above 10 or PHQ-9 above 10 in the absence of concurrent cognitive behavioral therapy for insomnia (CBT-I) or psychiatric medication adjustment predicts a high probability of continued non-response [5].

Step 4. Rule out circadian disorder. A 7-day actigraphy record combined with sleep diary data can differentiate delayed or advanced phase from true insomnia [8]. Patients whose sleep onset consistently occurs after 1 AM regardless of bedtime and who do not report early morning insomnia likely have a circadian disorder, not orexin-mediated hyperarousal.

When to Switch and What to Switch To

After a confirmed adequate trial, the prescriber has several evidence-based options.

Adding or Switching to CBT-I

The AASM and the American College of Physicians both recommend CBT-I as first-line treatment for chronic insomnia disorder, ahead of pharmacotherapy [5][9]. The 2016 ACP guideline states: "All adult patients receive CBT-I as the initial treatment for chronic insomnia disorder" [9]. Patients who have never undergone CBT-I and who fail lemborexant should be referred before any pharmacological switch.

A Cochrane review of 13 trials (N=1,073) found that CBT-I produced a mean reduction in ISI score of 8.4 points versus 2.1 points for pharmacotherapy alone, with effects durable at 12-month follow-up [10].

Suvorexant as an Alternative Orexin Antagonist

Suvorexant (Belsomra), the first approved dual orexin receptor antagonist, is not interchangeable with lemborexant, but some patients who fail lemborexant respond to suvorexant and vice versa [6]. The two drugs differ in half-life (suvorexant mean 12 hours vs. Lemborexant 17 to 19 hours) and receptor binding kinetics, which may matter in specific phenotypes [3][6].

Low-Dose Doxepin for Terminal Insomnia

For patients with early morning awakening as the dominant complaint, low-dose doxepin 3 to 6 mg (Silenor) has FDA approval specifically for sleep maintenance and has demonstrated efficacy in patients who did not respond adequately to other hypnotics [3][11]. Its mechanism (histamine H1 antagonism) is entirely distinct from orexin blockade, providing a rational non-overlapping pharmacological target [11].

Evaluating for Sleep Apnea

A subset of insomnia non-responders have undiagnosed obstructive sleep apnea (OSA). OSA prevalence in adults with chronic insomnia reaches 30 to 40% in some sleep clinic populations [12]. Lemborexant may actually worsen OSA by reducing upper airway muscle tone during sleep [3]. Patients who report non-restorative sleep, morning headaches, or bed-partner-reported apneas should undergo home sleep apnea testing before any further hypnotic prescribing.

A Note on Realistic Expectations Before Starting Lemborexant

Physicians at sleep medicine centers consistently report that patient expectation mismatch is one of the most correctable contributors to perceived non-response. Lemborexant does not produce the rapid, heavy sedation of benzodiazepines or z-drugs. Its onset is gradual. Patients who try to "fight" the medication by staying up to see if it works will often conclude it does not.

The prescribing information recommends taking lemborexant immediately before bed, with at least 7 hours remaining before the planned wake time, and only when ready for sleep [3]. Patients who take it while watching television or using a smartphone may not allow sufficient darkness and quiet for the orexin blockade to produce perceptible sleep onset.